Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2013-04-01 Director's Dealing
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2013-04-01 English
PRIMARY DOCUMENT
Director's Dealing
2013-04-01 English
PRIMARY DOCUMENT
Director's Dealing
2013-04-01 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, specifically a Current Report under the Securities Exchange Act of 1934. It includes an Item 2.02 which states that the company issued a press release containing financial information about results of operations and financial condition for the three and twelve months ended December 31, 2012. The document explicitly states that the press release is being furnished and not filed, and the actual financial details are in the press release (Exhibit 99.1), which is not included here. The 8-K itself is a brief regulatory filing notifying the market of the earnings release but does not contain the full financial results or detailed analysis. The document length is only 2256 characters, which is short and consistent with an announcement rather than a full report. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a brief announcement referencing a financial report (press release) but does not contain substantive financial data itself.
2013-03-29 English
FORM 10-K
Annual Report FY 2012
2013-03-29 English
PRIMARY DOCUMENT
Director's Dealing
2013-03-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.